Impact of quality items on study outcome. Treatment in acute lateral ankle sprains. by Verhagen, A.P. et al.
  
 
Impact of quality items on study outcome. Treatment
in acute lateral ankle sprains.
Citation for published version (APA):
Verhagen, A. P., de Bie, R. A., Lenssen, A. F., de Vet, H. C. W., Kessels, A. G. H., Boers, M., & van den
Brandt, P. A. (2000). Impact of quality items on study outcome. Treatment in acute lateral ankle sprains.
International Journal of Technology Assessment in Health Care, 16, 1136-1146.
https://doi.org/10.1017/S0266462300103174
Document status and date:
Published: 01/01/2000
DOI:
10.1017/S0266462300103174
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
International Journal of Technology Assessment in Health Care, 16:4 (2000), 1136–1146.
Copyright c° 2000 Cambridge University Press. Printed in the U.S.A.
IMPACT OF QUALITY ITEMS
ON STUDY OUTCOME
Treatments in Acute Lateral Ankle Sprains
Arianne P. Verhagen
Maastricht University and Erasmus University Rotterdam
Robert A. de Bie
Maastricht University
Anton F. Lenssen
Maastricht University Hospital
Henrica C. W. de Vet
Maastricht University and Vrije Universiteit
Alphons G. H. Kessels
Academic Medical Hospital
Maarten Boers
Vrije Universiteit and University Hospital
Piet A. van den Brandt
Maastricht University
Abstract
Objective: This study investigates the influence of different aspects of methodologic quality on the
conclusions of a systematic review concerning treatments of acute lateral ankle sprain.
Method: A data set of a systematic review of 44 trials was used, of which 22 trials could be included
in this study. Quality assessment of the individual studies was performed using the Delphi list. We
calculated effect sizes of the main outcome measure in each study in order to evaluate the relationship
between overall quality scores and outcome. Next, we investigated the impact of design attributes on
pooled effect sizes by subgroup analysis.
Results: The quality of most studies (82%) was low; only 4 of 22 trials were of high quality. Studies
with proper randomization and blinding procedure produce a slightly higher (not statistically significant)
effect estimate compared to the other studies.
Conclusion: Previous research has suggested that methodologically poorly designed studies tend to
over-estimate the effect estimate. Our study does not confirm these conclusions.
Keywords: Review, Methodology, Randomization, Blinding, Effect sizes
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Impact of quality on outcome
Are the conclusions of a systematic review influenced by the methodologic quality of the
included studies? Some researchers have not found any difference in results between studies
of good and poor quality (1;8;9). Others found that the methodologically sound studies
showed less positive treatment effects compared to studies with poor quality (4;10;11;14),
or vice versa (2).
Some research on the relationship between design attributes, such as randomization,
and outcome has already been performed. Kunz et al. (13) systematically summarized
empirical studies comparing randomized versus nonrandomized clinical trials and trials
with adequate concealed allocation versus inadequate concealed allocation procedures.
Of the latter comparison, most studies indicate that inadequate concealment results in an
overestimation of effects (5;16;17). Kunz et al. (13) concluded in their methodologic review
that “failure to use adequate concealed random allocation can distort the apparent effects
of care in either direction.”
A number of studies have examined the influence of blinding on outcome. Shapiro &
Shapiro (19) found that when the observer was blinded, the effect sizes were smaller com-
pared to studies with an unblinded observer. Colditz et al. (6) and Miller et al. (15) found
conflicting results in their studies. Colditz et al. (6) found lower effect sizes in double-blinded
studies compared with no blinding, while Miller et al. (15) found that “double blind compar-
isons produced the largest average gains (effect sizes), significantly larger than the average
for comparisons that involved no blinding.” Schulz et al. (18) concluded that lack of double
blinding resulted in an overestimation of effects. Also, Linde et al. (14) concluded that, of
the design characteristics tested using meta-regression techniques, double blinding had the
strongest influence on outcome; namely, double-blinded trials produced less positive results.
Most studies on design characteristics are performed outside the context of a specific
therapeutic research question (16;17;18). In this study we chose to place our research within
a specific research question, i.e., the efficacy of conservative treatments in acute lateral ankle
sprains, to create a more homogeneous data set concerning patients, disease, interventions,
and outcome measures. The purpose of this study is to evaluate whether overall trial quality
and trial design attributes, such as the randomization procedure and blinding, have an impact
on the conclusion of a systematic review.
METHODS
Studies
We used a data set from a systematic review (de Bie RA, Verhagen AP, et al. Efficacy of con-
servative interventions in the treatment of acute lateral ankle sprains: A systematic review.
Unpublished.) of 44 randomized clinical trials on the efficacy of conservative interventions
in the treatment of acute lateral ankle sprains. All studies were randomized and compared
conservative treatment with either no treatment, a placebo, or nonsurgical treatment. Trials
were excluded from this study when they presented a withdrawal rate greater than 50% or
when no effect sizes could be calculated.
Assessment of Methodologic Quality
For the assessment of the methodologic quality of individual studies, we used the Delphi
list presented in Table 1 (21). The quality score consists of the number of items satisfied
and ranges from 0–9. The assessment of the studies was performed independently by two of
the authors (APV, AFL) followed by a consensus meeting. Both reviewers have performed
quality assessment in other reviews and were therefore regarded as relatively experienced.
For the component analysis, studies were divided into several categories according to items
concerning the randomization procedure, blinding, and the analysis used. By appropriate
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Table 1. The Delphi List Used to Assess the Methodologic Quality of the Investigated Studies
1. Treatment allocation
a) Was a method of randomization performed? Yes/No/Don’t know
b) Was the treatment allocation concealed? Yes/No/Don’t know
2. Were the groups similar at baseline regarding the Yes/No/Don’t know
most important prognostic indicators?
3. Were eligibility criteria specified? Yes/No/Don’t know
4. Was the outcome assessor blinded? Yes/No/Don’t know
5. Was the care provider blinded? Yes/No/Don’t know
6. Was the patient blinded? Yes/No/Don’t know
7. Were point estimates and measures of variability Yes/No/Don’t know
presented for the primary outcome measures?
8. Did the analysis include an intention-to-treat analysis? Yes/No/Don’t know
randomization we mean that information about a proper randomization procedure is pre-
sented in the paper, instead of just using the word random. By concealed randomization we
mean that a random (unpredictable) allocation sequence is generated by an independent per-
son not responsible for determining eligibility of the patients, and this sequence is concealed
until allocation occurs (17). For blinding we divided the studies into two main categories:
blinding reported or not reported. When blinding is reported, we note whether the observer
was blinded or the term double blind was used. For the statistical analysis items, we divided
the studies into two categories: performance of an intention-to-treat (ITT) analysis or not.
Statistical Methods
For the primary outcome measures we calculated the effect sizes and their 95% confidence
intervals (CI) according to the methods described in Cooper and Hedges (7). These effect
sizes transform the results of continuous data from any parallel group comparison into a
standardized metric. For pooling we used one effect size out of each study. When one study
allowed for calculating two or more effect sizes, we preferably used pain as primary outcome
measure, and swelling if pain was not reported in the original study. Pooled effect sizes
were calculated according to a random effects model (7). In a funnel plot we evaluated the
possibility of publication bias in this review. If there is publication bias in a meta-analysis,
the funnel plot will often be skewed and asymmetrical (8).
Next we calculated overall quality scores (QS) for the individual studies by summing
up the “yes” scores. In advance, a cut-off point between “high” and “low” quality studies
is set at 50% of the maximum achievable score of 9 points, meaning high-quality studies
scored 5 points or more and low-quality studies 4 points or less. For the analysis of major
components of quality, i.e., randomization, blinding, and an ITT analysis, we performed
component analysis. For the pooling we used the primary outcome of each study.
RESULTS
Studies
Only 23 of the 44 studies allowed for calculation of effect sizes for one or more outcome
measures and were included. One study of the 23 (44), is excluded from the analysis
because of a high withdrawal rate: over 60% loss to follow-up after 3 months and over
80% after 1 year. The sample of excluded studies was comparable with the included ones
concerning patient characteristics, randomization schedule, blinding, interventions, and
outcome measures.
In total, five studies compared an intervention such as “short wave” or “laser therapy”
with a placebo and six studies compared “brace,” “tape,” or “bandage” with “cast” or
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Figure 1. Funnel plot of sample size against effect sizes of the individual studies.
“plaster.” In nine studies pain was reported as the main outcome measure, and in nine
studies swelling was reported as an outcome measure. All studies included patients with
acute ankle sprains (<48 hours).
Effect Sizes
In the 22 included studies we were able to calculate 27 effect sizes. Of these 27 effect
sizes, eight (29.6%) were negative, suggesting an effect in favor of the control group. Only
one outcome measure of each study, preferably pain, is used in the analysis. In Table 2 we
present the characteristics of all 22 studies and their main outcome measures, and effect
sizes. In order to assess potential publication bias, Figure 1 presents the funnel plot of the
effect sizes, as presented in Table 2, against the sample size. The sample size is presented
horizontally and the effect sizes vertically. The funnel plot shows no asymmetry; therefore,
we assume that our meta-analysis is probably not biased. The pooled estimate or the overall
average of effects is 0.28 (95% CI: 0.08–0.49).
Quality Scores
Table 2 presents the characteristics of the studies included. The Delphi quality scores
range from 1 to 6 points. The mean QS is 3.6, which is low compared to the maximum
achievable score of 9 points. Only 23% of the studies reported information about the method
of randomization and another 23% of the reports presented any information about blinding
procedures. Two trials reported information concerning both the randomization and blinding
procedures. All high-quality trials (nD 4) are placebo controlled trials. In the subgroup of
non–placebo-controlled trials, the mean QS is 3.1 (medianD 3).
The two reviewers, who assessed the articles independently, had an initial agreement
on the Delphi criteria list of approximately 95%. The 5% disagreement occurred mostly
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Figure 2. Plot of the Delphi QS of the individual studies against effect size.
because one reviewer had missed some information (4%), but rarely because of a difference
in interpretation of the information (1%).
Relationship Between Overall Quality and Outcome
We made a scatter plot between the overall quality scores and effect sizes (Figure 2).
The scatter plot shows no relation between the QS and the effect sizes (interceptD 0.217;
slopeD 0.045). The pooled effect size of high-quality studies (nD 4) is 0.53 (95%
CI: ¡0.21–1.27) and of low-quality studies (nD 18) is 0.19 (95% CI: 0.009–0.38). This
difference is not statistically significant. When we divide the subgroup of non–placebo-
controlled trials in high (nD 6) and low (nD 11) quality, using a cut-off score of the mean
QS (3.1; medianD 3), the pooled effect sizes are ¡0.14 (95% CI: ¡0.51–0.24) and 0.37
(0.14–0.61), respectively.
Component Analysis
The effect sizes, pooled for subgroups according to the various design attributes, are pre-
sented in Figure 3.
Randomization. Of all 22 studies, two reported a concealed randomization proce-
dure (32;34), and three an adequate method of randomization (23;37;41). Because of the
small numbers of studies in both categories, we combined them in the component analysis
(nD 5). Only one trial with a proper randomization procedure is regarded of high quality.
When the randomization method is unknown, the pooled effect size is lower (0.21; 95% CI:
0.00–0.44) than when the method is appropriate or concealed (0.34; 95% CI: 0.02–0.68).
Blinding. When double blinding is mentioned (28;34;38), all studies described at least
one level of blinding, and all described the method of blinding. Two studies (38;41) described
blinding of the outcome measurement (observer), and two studies (28;38) described
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Figure 3. Pooled effect size of all studies according to various design attributes.
blinding of two different levels. One study (28) evaluated whether the blinding proce-
dure was successful. Four of the five studies with a description of blinding are considered
of high quality. The pooled effect size for the category “blinding not reported” is lower
(0.19; 95% CI: 0.008–0.40) than when blinding is reported (0.46; 95% CI: ¡0.06–0.99)
and is comparably low with the pooled effect size in the category “randomization procedure
unknown” (Figure 3).
Analysis. In eight studies the performance of the analysis was carried out according
to the ITT principle. There is no difference in pooled effect size between studies with an
ITT and those with no ITT analysis (Figure 3).
DISCUSSION
This study evaluates the impact of design characteristics in systematic reviews. Retrospec-
tively, our data set appeared to be a less than ideal set of data for this purpose. Nevertheless,
some results are worth discussing. In general, design factors, such as proper randomization
and blinding procedures, do influence the interpretation of the results of individual clinical
trials. The use of design factors in the interpretation of aggregated research in systematic
reviews or meta-analysis is more difficult. In our study the overall methodologic quality
scores varied between poor and reasonably good (range between 11% and 66% of maximum
available score), but most studies (18 of 22) scored less than half of the maximum available
score. More important, we had to exclude 50% of the identified studies solely because
of a poor data presentation. Our findings support the conclusion of other researchers that
only a few clinical trials meet the minimum standards of methodologic rigor to be validly
interpretable from a scientific point of view (3;12;20).
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 16:4, 2000 1143
Verhagen et al.
A leading paradigm in empirical research is that clinical trials that do not meet some
design criteria, such as concealed randomization or double blinding, will be biased in favor
of the intervention, and will therefore more likely produce positive treatment effects. We
cannot confirm this paradigm. We found a trend, although not statistically significant, toward
a higher effect estimate in high-quality trials. Concerning design factors, we found a trend
toward a higher effect size in trials with an appropriate randomization procedure or where
blinding was reported, compared to the ones using an unknown randomization and blinding
schedule.
There are several possible explanations why our findings do not confirm this paradigm.
The validity of our investigation is limited by the small number of trials (nD 22), the small
number of patients involved, and the quality of the data presented. Our results could be
affected by the fact that we had to exclude almost half of our studies, because data enabling
calculation of effect sizes was not presented. However, the included and excluded studies
were similar with regard to the most important design characteristics. The difference in
effect size between high- and low-quality trials might be due to the difference in control
group: all high-quality trials were placebo-controlled trials.
Contrary to other studies addressing design characteristics (16;17), we chose to place
our research within a specific research question. This, and the exclusion of half of the
identified studies, resulted in a loss of power and may have increased the risk of a type II
error. Because of the small number of trials, we were unable to perform meta-regression
analysis on the separate design characteristics. According to Kunz et al. (13), evidence about
the influence of randomization is less clear in comparisons across interventions compared
to empirical studies using studies with more or less the same intervention. Combining trials
concerning varying interventions in varying diseases or disorders leads to such a large
heterogeneity that an estimation of an overall average of effects cannot be given. In that
case the assumption that nonconcealed randomized trials, or not-blinded trials, provide an
overestimation of the treatment effect cannot be tested.
The problem remains that we do not know what the “true” treatment effect is, we can
only estimate it. There are two possible ways of estimating a true effect size. One is to
infer it from the methodologic best studies. Another way is to assume that larger studies
present a more precise estimate of the true effect size and that the results of small trials
show a random variation around this true effect size. We based our decision about the
impact of design characteristics on the latter way of inferring a possible true effect size,
or the overall average of effects of 0.28 (95% CI: 0.08–0.49), because there were too few
adequate methodologic studies in this field. Stating this, the pooled estimates of the studies,
which reported a concealed or appropriate randomization or blinding procedure, provide
a slightly higher estimate compared to the overall average of effects. The pooled effect
estimate of the high-quality studies (0.53) only provides a much higher estimate of the
probable treatment effect, although not statistically significant.
Our research, although hampered by a lack of power, contributes to the (still very small)
body of scientific knowledge concerning quality assessment in clinical trials. Our data do
not confirm the leading paradigm in this field of research, that lack of proper randomiza-
tion and blinding lead to overestimation of effects. This means that the impact of design
characteristics is not clear and simple. We are convinced that empirical research should be
performed within a specific research question, hereby preventing heterogeneity caused by
a different study population, different interventions, or different outcome measures. The
resulting lack of power can be overcome in meta-analysis of empirical studies such as
performed by Kunz and colleagues (13).
In conclusion, we found a consistent trend, although not statistically significant, toward
a higher effect estimate in studies with higher quality or when randomization and blinding
procedures are properly done or described, respectively. The direction in effects we found
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were contrary to the ones suggested by the paradigm. Thus, the direction and magnitude of
this effect is unpredictable and may depend on the research question. Quality assessment
is seen as an important part of a meta-analysis, but the influence of quality on outcome
remains unclear and needs further research.
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